Ciltacabtagene autoleucel

PreclinicalCell therapy

Ciltacabtagene autoleucel is a cell therapy that works as a BCMA CAR-T.[2] It is being investigated across 1 indication, with its most advanced program in Preclinical.[1]

Ciltacabtagene autoleucel is one of 21 cell therapy programs targeting Multiple Myeloma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaUnknown

Multiple MyelomaPreclinical

Unknown

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 2

Adriamycin

GGynecologic Oncology Group

Preclinical

9 3

Nolvadex

AstraZeneca

Preclinical

1 4

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 5

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 6

Abecma

Bristol-Myers Squibb

Preclinical

4 7

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

2 8

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

1 9

Florbetaben

LLife Molecular Imaging GmbH

Preclinical

1 10

Imid Treatment

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Multiple Myeloma

NCT07093554

Q2 2028

Phase 1Recruiting

Multiple Myeloma

NCT06623630

Q3 2031

Phase 2Recruiting

Multiple Myeloma

NCT06940297

Q4 2037

Recruiting

Multiple Myeloma

NCT06855121

Clinical

Trials by Indication[1]

Multiple Myeloma4 trials

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·MMedical College of Wisconsin·Phase 1·NCT07093554·31 enrolled

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Recruiting·MMayo Clinic·Phase 2·NCT06940297·44 enrolled

The Norwegian Immunotherapy in Multiple Myeloma Study

Recruiting·SSt. Olavs Hospital··NCT06855121·400 enrolled

Show 1 more trial

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Recruiting·WWashington University School of Medicine·Phase 1·NCT06623630·16 enrolled

Myeloma1 trial

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Active, not recruiting·—·Phase 2·NCT05767359·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Ciltacabtagene autoleucel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ciltacabtagene autoleucel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ciltacabtagene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
[4]
PubMed — 2 publications indexed for Ciltacabtagene autoleucel. U.S. National Library of Medicine.
[5]
SEC EDGAR — St. Olavs Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: BCMA CAR-T[2]
Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: SSt. Olavs Hospital

Key Publications[4]

Two-Year Follow-Up of BCMA CAR-T in Multiple Myeloma

BloodAug 10, 2023DOI: 10.1182/blood.2023020145

Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: CARTITUDE-4

N Engl J MedJun 5, 2023DOI: 10.1056/NEJMoa2303379

Ciltacabtagene autoleucel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Q3 2031

Q4 2037

Trials by Indication[1]

Multiple Myeloma4 trials

Myeloma1 trial

References

Drug Info

Quick Facts

Key Publications[4]

Related News